ADE has been observed in SARS, MERS and other human respiratory virus infections, which suggests a real risk of ADE for SARS-CoV-2 vaccines and antibody-based interventions. Non-neutralizing mAbs against SARS-CoV-2 should be administered to determine whether non-neutralizing antibodies enhance disease.
Clinical and Translational Updates
Public Drug Information
First Brand Name
First Approved Country
First Approved Company
First Approved Date
5% Human Normal Immunoglobulin (Hemarus Therapeutics)